Form 4: SAB Biotherapeutics Director William James Polvino Receives Stock Option Grants

Director William James Polvino received stock option grants from SAB Biotherapeutics, Inc. on July 15, 2024, as part of his compensation as a board member.

Summary

• William James Polvino, a director at SAB Biotherapeutics, Inc., received two stock option grants on July 15, 2024.
• The first grant is an annual grant for 20,000 shares, vesting in two equal annual installments starting July 15, 2025.
• The second grant is a one-time grant for 13,958 shares, vesting in three equal annual installments starting July 15, 2025.
• Both options have an exercise price of $2.90 and expire on July 15, 2034.
• The grants were made under the company's 2021 Omnibus Equity Incentive Plan, as amended.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of stock option grants to a director, which is generally viewed neutrally. The grants are part of a standard compensation package and align the director's interests with shareholders.

Positives

• The grants align the director's interests with those of the shareholders, incentivizing him to work towards the company's long-term success.
• The vesting schedules encourage continued service on the board.

Industry Context

Stock option grants are a common form of compensation for directors of publicly traded companies, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Director compensation packages vary widely across the biotechnology industry depending on company size, stage of development, and board responsibilities.
• Comparing SAB Biotherapeutics' director compensation to peers like Vir Biotechnology or Emergent BioSolutions would provide a better understanding of its relative competitiveness.
• Stock option grants are a standard component of director compensation packages in the biotech industry.

Stakeholder Impact

• Shareholders may view the stock option grants positively as they incentivize the director to work towards increasing shareholder value.
• The grants have a dilutive effect on existing shareholders, although the impact is likely minimal.

Key Dates